When we talk with VBC directors and population health leadership at regional health systems, the conversation about ROI usually starts in the wrong place. The question I hear most often is "what's the cost savings per avoided readmission?" — and while that's a real number worth knowing, it's also a frame that makes the business case harder to build than it needs to be.
Avoided readmissions are difficult to attribute causally. When a patient doesn't get readmitted, you can never prove with certainty that your outreach prevented it versus the patient just having a good quarter. Finance teams will pick apart attribution arguments relentlessly, and correctly so — it's their job.
The stronger ROI framework doesn't start with what didn't happen. It starts with what your quality measures actually pay on.
The Shared Savings Math: Quality Multiplier First
For organizations in MSSP ACO contracts — Track 1, Track 1+, Enhanced, or any commercial analog — the financial performance equation has two inputs: total cost of care versus benchmark, and quality score performance.
The quality score component matters for a reason that is often underweighted in care gap ROI discussions: in MSSP Enhanced Track, quality performance determines what percentage of earned savings you actually receive. An ACO that generates $4M in gross shared savings but scores in the 70th percentile on quality will receive significantly less than one that scores in the 90th percentile. The quality multiplier on savings is real money, and it is directly impacted by your HEDIS measure performance on chronic disease management.
The specific HEDIS measures most affected by chronic disease patient engagement — Controlling High Blood Pressure (CBP), Comprehensive Diabetes Care (CDC), Medication Management for People with Asthma (MMA) — are all driven by whether your care team successfully maintains between-encounter contact with your attributed chronic disease population.
A 5-percentile improvement in CBP measure performance across a panel of 3,000 attributed hypertensive lives means approximately 150 additional patients classified as "controlled." Each of those closures represents a successful engagement event — a patient who was at risk of disengaging and didn't because someone reached them at the right time. In quality measure scoring terms, this directly affects your MSSP quality tier.
Building a Defensible Attribution Model
I'm not going to argue that care gap closure ROI is easy to measure with precision. It isn't. But there are proxy metrics that are both measurable and defensible to your finance team:
Care gap closure rate by outreach intervention type
How many patients on your hypertension or diabetes panel had an open HEDIS measure gap at the start of a quarter? How many closed by the end? What percentage of closures were preceded by an outreach event — a phone call, an SMS, a coordinator-initiated appointment — within 30 days of closure? This gives you an attribution window that doesn't require causal proof but does establish correlation between outreach activity and gap closure at a cohort level.
If your outreach-preceded closure rate is 40% higher than your passive closure rate (closures that happened without documented preceding outreach), you have a defensible basis for attributing incremental closures to outreach intervention. At scale, that differential has a quality score value you can calculate.
Medication adherence and acute event correlation
For patients on maintenance medications for hypertension (amlodipine, lisinopril, metoprolol, hydrochlorothiazide) or diabetes (metformin, semaglutide, empagliflozin), pharmacy fill data gives you a continuous adherence signal. Patients with PDC (proportion of days covered) below 80% have materially higher acute event rates than adherent counterparts — this relationship is well-established in the published literature on medication adherence and total cost of care.
The ROI question becomes: for patients who were drifting below 80% PDC and received an outreach intervention that brought them back to adherence, what was the reduction in subsequent acute event claims? You won't have a clean controlled trial, but you can build a matched comparison within your own panel — adherent patients versus lapsed-and-recovered patients versus chronically lapsed patients — and the cost differences are typically large enough to be meaningful even with conservative assumptions.
Avoided ED conversion rate
This is the attribution argument that actually works with finance teams: not "we prevented X readmissions," but "when we successfully reached a patient showing disengagement signals before an acute event, Y% of those patients had no subsequent acute ED or inpatient event in the following 90 days. Here's what the claims cost would have been if they had presented." It's a prospective tracking exercise, not a counterfactual claim.
The Cost Side of the Equation
Care gap closure ROI is a ratio, which means you have to be honest about the cost side too. The fully loaded cost of care coordinator outreach is higher than most organizations model.
A care coordinator making 20–25 outreach attempts per day at a fully loaded cost of $55,000–$70,000 annually generates roughly 5,000–6,000 meaningful contacts per year (accounting for no-answers, callbacks, and follow-up touches). The cost per successful contact closure is somewhere in the $10–$20 range, not including management overhead and documentation time.
Automated outreach — well-structured SMS campaigns with smart routing to clinical voice when escalation is needed — reduces the cost per contact significantly. But the business case shouldn't be sold primarily on cost reduction. Coordinators doing less administrative volume doesn't mean coordinators doing less valuable work; it means they're spending time on higher-complexity patients who genuinely need a human conversation.
The realistic ROI frame is: proactive outreach increases care gap closure rates (measurable), which improves HEDIS quality scores (measurable), which improves MSSP quality tier multipliers (financially quantifiable), while simultaneously reducing the downstream acute event claims that would have resulted from the gaps that closed (attributable with appropriate conservatism).
We're not saying you can book avoided-readmission savings as hard revenue in your budget model. Finance teams are right to be skeptical of that framing. What you can book is the quality score impact and the claims delta between your outreach-engaged and non-engaged patient cohorts.
Structuring the Internal Business Case
For VBC directors trying to build an internal case for expanded patient engagement investment, the structure that tends to work with health system finance leadership:
Start with current quality measure performance and the gap to next tier
Pull your current HEDIS quality scores for CBP, CDC, and MMA. Identify the score you'd need to reach the next performance tier in your MSSP contract. Calculate how many additional measure closures that requires. Express that in terms of patients and encounters — not percentile scores, which are abstract to finance leadership.
Show the outreach-to-closure conversion rate you've observed or can benchmark
If you have internal data, use it. If not, conservative benchmarks from published population health literature — somewhere in the 15–25% range for well-structured proactive outreach programs on previously lapsed patients — are defensible. Apply that conversion rate to the number of patients you'd need to engage to close the quality score gap.
Express the quality tier delta in dollars
For MSSP Enhanced Track, the quality multiplier on shared savings is calculable. If your ACO is generating $3M in gross shared savings and is currently at 70% quality performance, moving to 85% quality performance has a specific dollar value to the calculation. That number is the ceiling on what improved outreach is worth in the current contract year — and it's a number your finance team can audit.
Separate the quality ROI from the cost-of-care ROI
Keep these two arguments separate in your model. Quality score impact is more directly attributable and easier to defend. Cost-of-care impact — avoided readmissions, reduced ED utilization — is real but harder to attribute cleanly and should be presented as an additional potential return with conservative assumptions, not as the primary justification.
A Worked Example (Illustrative Ranges)
Consider an illustrative scenario for a regional health system managing an MSSP ACO with 8,000 attributed lives, approximately 2,200 of whom have diagnosed hypertension with open CBP care gaps at the start of the performance year.
If current CBP measure closure rate is 68% and the health system needs 74% to reach the next quality tier, that represents approximately 130 additional patients who need a qualifying controlled BP reading documented before year-end. At a 20% outreach-to-closure conversion rate, that requires contacting and successfully engaging roughly 650 patients — a 90-day outreach campaign targeting patients with the longest current gap and the highest prior engagement responsiveness.
The quality tier improvement from 68% to 74% in a reasonably sized MSSP contract could represent $150,000–$400,000 in additional shared savings depending on gross savings pool size. The cost of a 90-day targeted outreach campaign — coordinator time, tooling, SMS volume — is a fraction of that. The ratio works even at conservative conversion assumptions.
The specifics will be different for every organization. But the framework holds: quality score improvement is financially quantifiable, the patient engagement activity required to move it is estimable, and the ROI ratio is generally favorable when the outreach program is well-designed and targeted rather than applied uniformly to the whole panel.
Patientrig's risk scoring is built to help care teams find exactly that 650-patient target list — the patients where proactive engagement is both likely to succeed and most consequential for quality score performance — rather than treating every open care gap as equally worth a coordinator call. That prioritization is where the ROI lives.
